Profile data is unavailable for this security.
About the company
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
- Revenue in USD (TTM)2.52m
- Net income in USD-4.70m
- Incorporated2011
- Employees4.00
- LocationXenetic Biosciences Inc945 Concord St.FRAMINGHAM 01701United StatesUSA
- Phone+1 (781) 778-7720
- Websitehttps://www.xeneticbio.com/